UroGen Pharma Ltd. (NASDAQ:URGN – Get Free Report) insider Mark Schoenberg sold 3,789 shares of the company’s stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $15.74, for a total transaction of $59,638.86. Following the sale, the insider now directly owns 149,423 shares of the […]
Clal Insurance Enterprises Holdings Ltd lessened its stake in UroGen Pharma Ltd. (NASDAQ:URGN – Free Report) by 58.0% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 222,159 shares of the company’s stock after selling 307,229 shares during the quarter. Clal Insurance Enterprises Holdings […]
UroGen Pharma Ltd. (NASDAQ:URGN – Get Free Report) saw a large growth in short interest in December. As of December 31st, there was short interest totalling 3,550,000 shares, a growth of 15.6% from the December 15th total of 3,070,000 shares. Based on an average trading volume of 263,700 shares, the short-interest ratio is currently 13.5 […]
Meitav Investment House Ltd. trimmed its holdings in UroGen Pharma Ltd. (NASDAQ:URGN – Free Report) by 13.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 91,456 shares of the company’s stock after selling 14,056 shares during the quarter. Meitav Investment House […]
Meitav Investment House Ltd. reduced its stake in UroGen Pharma Ltd. (NASDAQ:URGN – Free Report) by 13.3% in the third quarter, HoldingsChannel reports. The fund owned 91,456 shares of the company’s stock after selling 14,056 shares during the quarter. Meitav Investment House Ltd.’s holdings in UroGen Pharma were worth $1,295,000 at the end of the […]